Letter to the EditorOutcomes of pharmacogenetics-guided dosing of warfarin: A systematic review and meta-analysis
References (11)
- et al.
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis
Int J Cardiol
(2013) - et al.
A randomized controlled trial of genotype-based Coumadin initiation
Genet Med
(2011) - et al.
Laboratory and clinical outcomes of pharmacogenetic vs clinical protocols for warfarin initiation in orthopedic patients
J Thromb Haemost
(2008) - et al.
A randomized trial of genotype-guided dosing of warfarin
N Engl J Med
(2013) - et al.
A pharmacogenetic versus a clinical algorithm for warfarin dosing
N Engl J Med
(2013)
Cited by (22)
Personalized Medicine in Cardiovascular Disease
2016, Diagnostic Molecular Pathology: A Guide to Applied Molecular TestingClinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials
2015, Thrombosis ResearchCitation Excerpt :However, the more important end points, the rates of bleeding and thrombotic complications, were still beyond the power design of these trials [19]. Recent published meta-analyses explored the effects of genotype-based warfarin dosing on clinical outcomes [20–24], which provided valuable, however in certain circumstances also conflicting results. Thus, whether PG algorithm-based strategy in patients initiating anticoagulant therapy with warfarin lead to more precise dosing and, by extrapolation, reduce the risk of thrombotic and bleeding complications is still in controversy.
Oral anticoagulation: A critique of recent advances and controversies
2015, Trends in Pharmacological SciencesCitation Excerpt :These studies have employed different inclusion and exclusion criteria and thus have included different numbers of trials and patients. Consequently the findings have also been discordant: while Franchini et al. [55] and Tang et al. [57] reported that genotype guided-dosing had some benefits, the other two [56,58] failed to show a difference between control and genotype dosing arms. Although the meta-analyses have used the heterogeneity statistic I2 as a measure of heterogeneity, arguably in the context of complex algorithms which differ considerably from one another, this is not an adequate measure for evaluating the heterogeneity.
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis
2022, Pharmacogenomics JournalWarfarin dosing algorithms: A systematic review
2021, British Journal of Clinical PharmacologyVariants in cdhr3, cacnac1, and lta genes predisposing sensitivity and response to warfarin in patients with cardiovascular disease
2021, International Journal of General Medicine